John Quigley
Hematology · Chicago, ILNPI 1912010323
Payments from drug & device makers
Across 275 payments — averaging $12,004 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.4M
- AbbVie$1.3M
- Teva Pharmaceuticals USA, Inc.$264K
- Novartis$99K
- Beigene, Ltd.$88K
- Servier Pharmaceuticals LLC$45K
- plus $154K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $1,384,919 |
| AbbVie | 42 | $1,266,104 |
| Teva Pharmaceuticals USA, Inc. | 8 | $263,828 |
| Novartis | 6 | $98,934 |
| Beigene, Ltd. | 9 | $88,038 |
| Servier Pharmaceuticals LLC | 33 | $45,209 |
| Daiichi Sankyo Inc. | 47 | $38,229 |
| Agios Pharmaceuticals, Inc. | 36 | $34,055 |
| Sanofi US Services Inc. | 2 | $26,014 |
| Alnylam Pharmaceuticals Inc. | 19 | $13,528 |
| Amgen | 10 | $9,091 |
| Jazz Pharmaceuticals Inc. | 10 | $7,441 |
| AstraZeneca | 7 | $4,608 |
| Sanofi | 4 | $4,429 |
| Recordati_rare_diseases_inc. | 2 | $4,000 |
| Tanabe Pharma America, Inc. | 1 | $3,075 |
| Bristol Myers Squibb | 4 | $2,821 |
| Rigel Pharmaceuticals, Inc. | 4 | $1,743 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Johnson & Johnson | 4 | $1,483 |
| Dova Pharmaceuticals | 3 | $1,451 |
| Beigene USA, Inc. | 2 | $176 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $115 |
| Merck | 3 | $62 |
| Portola Pharmaceuticals, LLC | 1 | $50 |
| Genentech USA, Inc. | 1 | $26 |
| Seagen Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
How this compares
$3,301,191 in reported general payments places this provider in the 95th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Chicago
- Deborah KatzChicago$3.3M
- Seema SinghalChicago$2.5M
- Nadia KhanChicago$2.2M
- Olga FrankfurtChicago$1.4M
- Seo-Hyun KimChicago$1.1M
- Parameswa VenugopalChicago$896K
- Martin TallmanChicago$743K
- Celalettin UstunChicago$699K
- Jagoda JasielecChicago$674K
- Brady SteinChicago$515K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.